Metabolic Disorders News and Research

RSS

Revisional bariatric surgery linked to higher risk of complications

Revisional bariatric surgery appears to be associated with a higher risk of complications than the initial procedure, according to a report in the February issue of Archives of Surgery, one of the JAMA/Archives journals.

16 Feb 2010

New campaign against childhood obesity: AACE lauds First Lady's efforts

The American Association of Clinical Endocrinologists (AACE) welcomes and applauds the effort of First Lady Michelle Obama, who announced a new campaign to combat childhood obesity today.

10 Feb 2010

Autism Speaks: Ten most significant autism research achievements in 2009

Autism Speaks, the world's largest autism science and advocacy organization has released its annual list of the 10 most significant research achievements to have impacted autism during the previous year. Every year, Autism Speaks documents the progress made toward its mission to discover the causes and treatment for autism spectrum disorders, and compiles a list of the 10 most significant research achievements to have impacted autism during the previous year.

10 Feb 2010

Entelos awarded U.S. patent for apparatus and methods of assessing metabolic substrate utilization

Entelos, Inc., a simulation and modeling company focused on human health, announced today that the U.S. Patent and Trademark Office has granted U.S. Patent No. 7,654,955 entitled “Apparatus and Methods for Assessing Metabolic Substrate Utilization” to the Company. These methods further strengthen the Entelos® Metabolism PhysioLab® platform and leverage insights about human physiology that can lead to improved diagnosis, clinical testing, and personalized treatment across a highly variable patient population.

2 Feb 2010

ADA's position paper addresses nutrition aspects of health care for people with developmental disabilities

The American Dietetic Association has published an updated position paper that addresses the nutrition aspects of health care for people with developmental disabilities and special health care needs.

2 Feb 2010

Amarin reviews 2009 accomplishments; outlines strategy for 2010 and beyond

Amarin Corporation plc, a clinical-stage biopharmaceutical company focused on improving the treatment of cardiovascular disease, today issued a special letter to its shareholders.

28 Jan 2010

Findings may provide new insights into diabetes; suggest novel targets for drug intervention

The neuropeptide corticotropin-releasing factor (CRF) makes cameo appearances throughout the body, but its leading role is as the opening act in the stress response, jump-starting the process along the hypothalamus-pituitary-adrenal (HPA) axis. Researchers at the Salk Institute for Biological Studies have found that CRF also plays a part in the pancreas, where it increases insulin secretion and promotes the division of the insulin-producing beta cells.

22 Jan 2010

HDL launches new preventative model to help physicians manage chronic diseases

Health Diagnostic Laboratory Inc. (HDL), www.hdlabinc.com, announced today the launch of its new preventative model to chronic disease management based off a monumental shift in the way physicians test for life threatening conditions.

19 Jan 2010

Metabolon awarded US Patent for ‘metabolomics methods’

Metabolon, Inc., the leader in global metabolism through biomarker discovery and analysis, today announced that it was awarded US Patent 7,635,556 “Methods for Drug Discovery, Disease Treatment and Diagnosis Using Metabolomics” by the United States Patent and Trademark Office on December 22, 2009.

18 Jan 2010

NIH, D.C. Department of Health partner to decrease the rate of new HIV infections

Officials from the National Institutes of Health and the city of Washington, D.C. today announced the new D.C. Partnership for HIV/AIDS Progress, a collaborative research initiative between NIH and the D.C. Department of Health designed to decrease the rate of new HIV infections in the city, improve the health of district residents living with HIV infection, and strengthen the city's response to the HIV/AIDS epidemic.

13 Jan 2010

Amarin commences enrollment in its AMR101 Phase 3 clinical trials for cardiovascular disease

Amarin Corporation plc, a clinical-stage biopharmaceutical company focused on improving the treatment of cardiovascular disease, today announced that first patients were enrolled in the MARINE and ANCHOR Phase 3 clinical trials for AMR101, the Company's lead product candidate. These clinical trials are designed to demonstrate that AMR101 lowers triglyceride levels in patients with very high triglycerides (the MARINE Study) and high triglycerides in patients with mixed dyslipidemia being treated with statins (the ANCHOR Study).

11 Jan 2010

Medtronic invests in GI Dynamics to advance treatment for metabolic disorders

GI Dynamics, a leader in non-surgical treatments for type 2 diabetes and obesity, today announced that it has received a strategic investment from Medtronic, Inc., the global leader in medical device technology and therapies designed to treat chronic diseases.

8 Jan 2010

Scientists identify new gene variants associated with disturbances in lipid metabolism

Scientists of Helmholtz Zentrum München led by Professor Karsten Suhre have identified new gene variants associated with disturbances in the lipid metabolism.

28 Dec 2009

Research uncovers structural basis for multifunctionality of aminoacyl tRNA synthetases

Research published in the December 13, 2009 edition of Nature Structural Biology uncovers the structural basis for the multifunctionality of aminoacyl tRNA synthetases. Aminoacyl tRNA synthetases are universal and essential enzymes of protein synthesis machinery found in all organisms.

14 Dec 2009

MHI launches new research program in heart failure

The Montreal Heart Institute (MHI) and its Foundation (MHIF) launched today the Carolyn and Richard J. Renaud Research Chair in Heart Failure, the first of its kind in Québec.

14 Dec 2009

Epizyme closes Series B financing to a total of $40 million

Epizyme, Inc., a biopharmaceutical company translating key discoveries in the field of epigenetics into novel pharmaceutical agents, announced today the participation of New Enterprise Associates (NEA) in its Series B, bringing the total financing to $40M.

9 Dec 2009

Cedars-Sinai Regenerative Medicine Institute supplies stem cells to aid Huntington's disease research

The Cedars-Sinai Regenerative Medicine Institute is to provide stem cells to a five-member National Institutes of Health consortium of researchers for development of potential therapies to treat Huntington's disease.

8 Dec 2009

New Center for Digestive Care to care for all aspects of digestive disease

The Center for Digestive Care at NewYork-Presbyterian Hospital/Weill Cornell Medical Center has been established with a mission to provide high-quality patient care, research and education for all aspects of digestive disease.

4 Dec 2009

Santaris Pharma's LNA technology based microRNA-targeted therapy holds promise for HCV

A study published online in this week's Science shows that SPC3649, a breakthrough microRNA-targeted therapy developed by Santaris Pharma A/S using its proprietary Locked Nucleic Acid (LNA) technology, holds promise as a novel treatment for patients infected with the Hepatitis C virus (HCV).